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The complete assignment of the proton chemical shifts obtained by nuclear magnetic resonance (NMR)
spectroscopy of de-O-acetylated glucuronoxylomannans (GXMs) from Cryptococcus neoformans permitted the
high-resolution determination of the total structure of any GXM. Six structural motifs based on an a-(133)-
mannotriose substituted with variable quantities of 2-O-b- and 4-O-b-xylopyranosyl and 2-O-b-glucopyrano-
syluronic acid were identified. The chemical shifts of only the anomeric protons of the mannosyl residues
served as structure reporter groups (SRG) for the identification and quantitation of the six triads present in
any GXM. The assigned protons for the mannosyl residues resonated at clearly distinguishable positions in the
spectrum and supplied all the information essential for the assignment of the complete GXM structure. This
technique for assigning structure is referred to as the SRG concept. The SRG concept was used to analyze the
distribution of the six mannosyl triads of GXMs obtained from 106 isolates of C. neoformans. The six mannosyl
triads occurred singularly or in combination with one or more of the other triads. The identification and
quantitation of the SRG were simplified by using a computer-simulated artificial neural network (ANN) to
automatically analyze the SRG region of the one-dimensional proton NMR spectra. The occurrence and
relative distribution of the six mannosyl triads were used to chemotype C. neoformans on the basis of subtle
variations in GXM structure determined by analysis of the SRG region of the proton NMR spectrum by the
ANN. The data for the distribution of the six SRGs from GXMs of 106 isolates of C. neoformans yielded eight
chemotypes, Chem1 through Chem8.
Cryptococcus neoformans is an opportunistic pathogenic
yeast. In most healthy individuals the organism does not
progress beyond the lungs, its normal portal of entry. Hema-
togenous dissemination occurs in patients who are immuno-
suppressed due to immunotherapy or some form of immuno-
deficiency (38, 44, 52). AIDS patients are vulnerable to
opportunistic infections due to the precipitous decline in the
competency of the immune system (35). Consequently, the
occurrence of cryptococcosis has increased dramatically, con-
comitantly with the emergence of AIDS (24, 41, 67). Despite
antifungal therapy, AIDS patients with cryptococcosis are ex-
tremely susceptible to relapse. With the exception of Pneumo-
cystis carinii, cryptococcosis is the most common invasive life-
threatening fungal infection associated with AIDS (27); it is a
leading cause of death in these patients (25). The yeast has a
propensity to involve the central nervous system, where it
causes meningoencephalitis (26, 48). Other frequent sites of
infection are the liver and spleen. Diagnosis of cryptococcosis
in an AIDS patient may portend the progression to further
immunosuppression and to a more severe phase of the disease
(47). The insidious association of cryptococcosis with AIDS
has resulted in increased attempts to define the virulence fac-
tors associated with the yeast and the host at the molecular
level.
C. neoformans is atypical of pathogenic fungi in that it pro-
duces a well-developed polysaccharide capsule (18, 60). The
major capsular polysaccharide is glucuronoxylomannan (GXM),
which is an important contributor to the virulence of C. neo-
formans (60). GXM is antiphagocytic (20, 36) and poorly im-
munogenic (37, 45), and acapsular strains have diminished
virulence (32). In vitro, GXM inhibits leukocyte migration
(28), enhances human immunodeficiency virus (HIV) infection
in human lymphocytes (46, 47), induces the release of tumor
necrosis factor alpha by peripheral-blood mononuclear cells
(21, 42), and promotes L-selectin shedding from neutrophils
(28).
Two distinct varieties of C. neoformans have been described:
C. neoformans var. neoformans and C. neoformans var. gattii
(39). The two varieties were subdivided serologically into four
serotypes based on the reactivities of whole yeast cells to poly-
clonal sera that were prepared by selective absorption with
whole yeast cells (31, 33, 68). The variety neoformans consists
of serotypes A, D, and A/D, and the variety gattii consists of
serotypes B and C. Most cryptococcal infections in AIDS pa-
tients are due to C. neoformans var. neoformans, with serotype
A comprising the majority of isolates (19, 40, 51, 57). Mono-
clonal antibodies and factor sera react specifically with GXMs.
These observations substantiate the role GXMs play in con-
ferring serotypes on C. neoformans.
The presence of at least eight antigenic factors, distributed
among the serotypes of C. neoformans, has been proposed
based on the reactivities of factor sera in yeast cell agglutina-
tion reactions (33). No structure corresponding to any one of
the eight antigenic factors has been delineated.
The typical GXM consists of a linear (133)-a-D-mannopy-
ranan bearing b-D-xylopyranosyl (Xylp), b-D-glucopyranosyl-
uronic acid (GlcpA), and 6-O-acetyl substituents (18, 60, 63).
The disposition of the O-acetyl substituents is the major de-
terminant of the antigenic activity observed among GXMs
* Corresponding author. Mailing address: Department of Chemis-
try, Georgia State University, University Plaza, Atlanta, GA 30303.
Phone: (404) 651-3868. Fax: (404) 651-1416. E-mail: cherniak@gsu
.edu.
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obtained from all serotypes (A, B, C, D, and A/D) (15). Gen-
erally, the serological activity observed with type-specific anti-
body is lost after de-O-acetylation (15, 36). Despite consider-
able structural and antigenic diversity, a simple structural
relationship exists between GXMs of reference isolates for the
four serotypes. They are all comprised of a core repeating unit
(Fig. 1) to which (132)-linked and (134)-linked b-D-Xylp
units are added in increments of one to four residues. In this
way, explicit molar ratios of Xyl/Man/GlcA in serotypes D, A,
B, and C have been assigned as 1:3:1, 2:3:1, 3:3:1, and 4:3:1,
respectively (Fig. 2, M1 through M4) (18). GXM from sero-
types A and D are mainly substituted with Xylp at O-2,
whereas GXM from serotypes B and C are substituted at O-2
and at O-4. Additional analytical data show that the precise
molar ratios and typical substitution patterns, as proposed in
the original models of GXM structure, are an oversimplifica-
tion. In addition, substituent dispositions previously thought to
be characteristic of one serotype have been identified in het-
erologous isolates (23, 24, 62, 63).
The primary sequences of de-O-acetylated GXMs from se-
rotypes A, B, C, and D were determined previously by two-
dimensional (2D) nuclear magnetic resonance (NMR) spec-
troscopy (11, 56, 58, 59), and the assignments of the 1H and 13C
chemical shifts were reported. These data, in conjunction with
earlier chemical and NMR analyses of GXMs, document the
existence of antigenic multiplicity among the serotypes, partic-
ularly in serotypes A and C (11, 24, 62). GXMs within a
particular serotype cannot be subdivided serologically because
factor sera and monoclonal antibodies have low discriminatory
power for determining structural heterogeneity (15, 17). Con-
sequently, the variation in GXM structure, as determined se-
rologically, cannot be correlated to the range of virulence ob-
served among C. neoformans isolates.
The complete assignment of the proton chemical shifts for
the structural elements present in various GXMs permits the
high-resolution determination of the total structure of any
GXM. In addition, the primary structural assignment of GXM
can be made by using only the anomeric protons of the man-
nose residues. This is based on the fact that the assigned
proton chemical shifts for the mannose residues resonate at
clearly distinguishable positions in the spectrum and supply all
the information essential for the assignment of the complete
FIG. 1. The core repeating structure of GXM.
FIG. 2. The six mannosyl triads found in GXMs of C. neoformans.
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structure. This technique is referred to as the structural re-
porter group concept (SRG) (65, 66).
The identification and quantitation of the SRG can be sim-
plified by using a computer-simulated artificial neural network
(ANN) (53) to automatically analyze 1D proton NMR spectra
as illustrated in Fig. 3. The 1D proton NMR spectrum serves as
the input data for the ANN, and the ANN produces an output
that represents the relative ratio of each SRG. The selection of
an ANN to predict the chemotype of C. neoformans is not
arbitrary. ANNs are extremely flexible in design, size, and
method of training. The ANN is trained with data (1D proton
NMR spectra) that define the structure of the polysaccharides
obtained by conventional analytical methods.
ANN is a network that consists of simple processing ele-
ments (PEs) and connecting elements that provide communi-
cation between the PEs (53). The PEs are also referred to as
“artificial neurons” or simply “neurons,” and the connecting
elements are referred to as “synaptic pathways” or “synaptic
connections” (53).
ANNs are ideal for extracting distinguishing features from
complex data patterns. ANNs have been used for a variety of
classification and identification tasks, including the identifica-
tion of NMR spectra of polysaccharides and other spectral
data (43, 49, 50, 54, 61), the diagnosis of diseases (1–8, 14, 15),
and other classification problems (8–10, 13, 29, 55, 64). This
article describes the development of a computer-simulated
ANN for the quantitative analysis of GXM fine structure by
using the proton NMR SRG concept. The data were used to
develop a chemotyping system based on the quantitation of the
subtle variations in GXM structure that occur in C. neoformans
isolates. The ANN is potentially a powerful tool for investigat-
ing the impact that the variation in the fine structure of GXM
from any particular isolate has on the effects observed with in
vitro and in vivo biological systems.
MATERIALS AND METHODS
GXM. C. neoformans isolates used in this study are listed in Table 1. Many
GXMs were available from earlier studies (11, 15, 23, 24, 58, 59, 62). GXMs from
C. neoformans isolates not studied previously were prepared as described else-
where (56). A streamlined method for the isolation of GXM from selected
isolates was used also. C. neoformans isolates were expanded in 50 ml of the
chemically defined liquid medium (22). After 5 days, the culture was autoclaved
for 25 min at 121°C and the cells were removed by centrifugation (at 18,000 3 g)
for 1 h. The culture supernatant (;50 ml) was adjusted to 0.2 M NaCl, and 0.15 g
of cetyltrimethyl ammonium bromide (CTAB) was added to the stirred solution
at 23°C. A 0.05% solution of CTAB (100 ml) was added slowly, with stirring. The
precipitate was recovered by centrifugation (at 5,000 3 g) for 15 min at 23°C. The
pellet was triturated with 10% ethanol, and the suspension was centrifuged as
described above. The pellet was dissolved in 1 M NaCl (25 ml) by stirring
overnight. GXM was precipitated by the slow addition of 3 volumes of 95%
ethanol, and the flask was placed at 4°C. The GXM was recovered by centrifu-
gation (at 5,000 3 g) for 15 min at 4°C. All preparations of GXM were dissolved
in 1 M NaCl (;25 ml), treated by ultrasonic irradiation (with a Branson Sonifier,
model 450) for 2 h at 80% power and 40% pulse at a temperature below 20°C,
dialyzed, and recovered by lyophilization. A portion of each GXM was de-O-
acetylated at pH 11 (NH4OH) for 24 h at 23°C (24), dialyzed, and lyophilized.
De-O-acetylated GXMs previously treated by ultrasonic irradiation were used in
all subsequent NMR experiments. The apparent average molecular mass of the
GXMs used for NMR analysis was 1.2 3 105 Da.
GXMs isolated in prior studies and those specifically selected for use in this
investigation are referenced in Table 1. The serotype of each GXM, whether
determined previously or by dot enzyme assay (16) as part of this study, is given
in Table 1.
NMR spectroscopy. De-O-acetylated GXMs (;10 mg) were exchanged in
99.9% D2O and lyophilized. Each sample was dissolved in 0.80 ml of 99.96%
D2O, then filtered through a Millipore MILLEX-GS 0.22-mm-pore-size filter,
and the filtrate was transferred into a 5-mm-diameter NMR tube (Wilmad
528-PP). All 1H NMR experiments were performed at 80°C on a Varian VXR-
400 or on a Varian Unity1500 spectrometer equipped with a 5-mm 1H/19F
probe. 1H chemical shifts were measured relative to internal sodium 4,4-dimeth-
yl-4-silapentane-1-sulfonate taken as 0.00 ppm. The data were processed off-line
by using a FELIX 2.30 software package (Biosym/Molecular Simulations, San
Diego, Calif.) on a Silicon Graphics Indy workstation. Each spectrum was res-
olution enhanced by applying a sine bell window function over all real data
points. The portion of each proton spectrum between 5.00 and 5.40 ppm, where
only the mannosyl residues resonate, was analyzed separately. This is the SRG
that was used to identify the specific saccharide sequences present in a particular
GXM.
Quantitation of each proton NMR signal in the SRG region required the
analysis of the NMR spectrum prior to resolution enhancement. The proton
NMR data were processed without a window function, and the full spectrum was
saved as a FELIX ASCII file. The FELIX ASCII file was transferred to a desktop
computer, where it was converted to ordered-pair data (chemical shift, intensity).
The ordered-pair data (x, y) were imported into PeakFit 4.0 (Jandel Scientific,
Inc., San Rafael, Calif.). Data in the SRG region (5.0 to 5.4 ppm) were selected,
and the remaining data were discarded. The data in the SRG region were
analyzed with the Autofit Peaks I selection (by using Lorentzian functions). The
peaks designated by PeakFit were processed manually based on the assignment
of the chemical shifts of the SRG regions, determined previously from the
resolution-enhanced spectra (see above). Rough fitting was done visually after all
the peaks were selected. Final data analysis was done with the Marquardt-
Levenberg fitting algorithm. The chemical shifts of the resolved peaks and their
corresponding areas for GXM were saved as an ASCII file. The data were used
to quantitate the presence of particular SRGs in GXM.
ANN. In this study we used a universal ANN design that consisted of a
two-stage feed-forward neural-network topology and the standard, backpropa-
gation training algorithm (53), as well as a modified version. Some parameters,
such as hidden layer size, step size, etc. (53) were optimized experimentally. The
final step was to train the ANN by using the optimum parameters.
FELIX ASCII files representing the 1H NMR spectra for GXMs obtained
from 106 individual C. neoformans isolates were divided into a training set (69
spectra) and a testing set (37 spectra). The SRG region of the NMR data was
used for the training set. The results of the PeakFit analysis (percent each SRG)
FIG. 3. ANN configuration for the analysis of the GXM NMR data for determining the chemotype of C. neoformans.
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were used as the desired output data. Each file was submitted individually, via the
Complex Carbohydrate Research Center’s web site (http://www.ccrc.uga.edu) by
using a web browser (such as Netscape Navigator), for analysis by the trained
neural network. A report page containing the percentage of each SRG in the
sample data was generated by the neural network. The output of the trained
neural network was compared to the data obtained independently by PeakFit.
The initial experiments used the standard backpropagation training algorithm
described by Rumelhart and McClelland (53). However, a modification to the
definition of the error function improved the performance of the ANN. This
modification included an additional mathematical term that required that the
sum of the SRG ratios add up to 100%. The final ANN was trained with this
modification. The trained ANN was cross-validated (53) with 1H NMR data
which were not part of the training set. The purpose of cross-validation was to
determine when to terminate training.
TABLE 1. C. neoformans isolates used in this study
Isolate Serotype Source
6 A T. G. Mitchell (Duke University)
18 B/C K. J. Kwon-Chung (National Institutes of
Health)
34 C K. J. Kwon-Chung
98 A T. G. Mitchell
110 A/D T. G. Mitchell
118 A T. G. Mitchell
127 D E. Jacobson (Medical College of
Virginia)
132 A/D T. Shinoda (Meiji College of Pharmacy,
Tokyo, Japan)
150 A T. G. Mitchell
184 B K. J. Kwon-Chung
194 A T. G. Mitchell
196 A K. J. Kwon-Chung
201 A K. J. Kwon-Chung
298 C K. J. Kwon-Chung
298 Warty B.Ca R. Cherniak (Georgia State University);
derived from 298
371 A K. J. Kwon-Chung
401 C K. J. Kwon-Chung
409 B E. Reiss (Centers for Disease Control
and Prevention)
430 D K. J. Kwon-Chung
1254 D E. Reiss
3168b D E. Reiss
3183 C E. Reiss
3939 B E. Reiss
9375 D H. J. Shadomy (Medical College of
Virginia)
9759 A E. Reiss
9759a A R. Cherniak; subculture of 9759
24067 a D A. Casadevall (Albert Einstein College of
Medicine)
24067 b D A. Casadevall
24067 c D A. Casadevall
24067 d1 D A. Casadevall
24067 d2 D A. Casadevall
24067 e D A. Casadevall
24067 f1 D A. Casadevall
24067 f2 D A. Casadevall
24067 g D A. Casadevall
A104 A T. R. Kozel (University of Nevada, Reno)
A271 A T. R. Kozel
A288 A T. R. Kozel
A289 A T. R. Kozel
A24064 A T. R. Kozel
ATCC 6352 A F. I. Molina (American Type Culture
Collection)
ATCC 24065 B F. I. Molina
ATCC 24066 B/C F. I. Molina
ATCC 28958 D F. I. Molina
ATCC 32269 B F. I. Molina
ATCC 32608 C F. I. Molina
ATCC 34875 D F. I. Molina
ATCC 34878 B F. I. Molina
ATCC 34880 C F. I. Molina
ATCC 48184 A/D F. I. Molina
ATCC 62066 A F. I. Molina
ATCC 90126 A/D F. I. Molina
AW A S. Levitz (Boston University Medical
Center)
B3502 D K. J. Kwon-Chung
B4538 A K. J. Kwon-Chung
C917 C T. R. Kozel
C24066 C T. R. Kozel
C24066T C R. Cherniak; derived from C24066
C24066W B/C R. Cherniak; derived from C24066
Continued
TABLE 1—Continued
Isolate Serotype Source
CDC92-64 A/B/D M. E. Brandt (Centers for Disease
Control and Prevention)
CDC92-159 D M. E. Brandt
CDC92-162 A/B/D M. E. Brandt
CDC92-187 A/B/D M. E. Brandt
CDC92-232 D M. E. Brandt
D52 D T. R. Kozel
D529 D T. R. Kozel
D24067 D T. R. Kozel
F12 D E. Jacobson
F27 A J. Murphy (University of Oklahoma)
F113 A J. Murphy
F117 A J. Murphy
Houpt 24066 B/C T. R. Kozel
J9a D A. Casadevall
J9b D A. Casadevall
J9c D A. Casadevall
J9d D A. Casadevall
J11a A A. Casadevall
J11b A A. Casadevall
J22a A A. Casadevall
J22b A A. Casadevall
Kuhl 94-8069 B J. Murphy
M0010 A T. G. Mitchell
M0013 A T. G. Mitchell
M0024 A/D T. G. Mitchell
M0025 A T. G. Mitchell
M0027 A T. G. Mitchell
M0029 A T. G. Mitchell
M0046 A T. G. Mitchell
M0048 A T. G. Mitchell
M0050 D T. G. Mitchell
M0051 A T. G. Mitchell
M0053 A T. G. Mitchell
M0062 A T. G. Mitchell
M0095 A T. G. Mitchell
MU-1 A R. Cherniak; derived from 9759
NCPF 3168 A A. Verheul (University Hospital,
Utrecht, The Netherlands)
NIH 37 A A. Verheul
NU-2 A J. Murphy
P0 NDc A. Casadevall
R1064 A K. J. Kwon-Chung
SB4a A.D A. Casadevall
SB4b A.D A. Casadevall
SB4c D A. Casadevall
SB6a D A. Casadevall
SB6b A/D A. Casadevall
TYCC 38-602 A K. J. Kwon-Chung
a B.C, activity with B greater than activity with C.
b Submitted to us as serotype A but chemically and serologically identical to
serotype D.
c ND, not determined.
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RESULTS
SRGs. The complete assignment of the proton NMR chem-
ical shifts for all the sugar residues present in GXMs selected
from a broad range of C. neoformans isolates has been de-
scribed previously (11, 12, 56, 58, 59). Based on the analysis of
these data, we identified six recurring triad structures. The first
mannosyl residue from the nonreducing end of a triad substi-
tuted at O-2 with b-D-glucuronic acid was always labeled Ma
(see Fig. 1). For the development of the C. neoformans che-
motyping system, the six structural triads were designated M1
through M6 (Fig. 2). The proton chemical shifts of the man-
nosyl residues characteristic of the six triads were obtained
from our previous studies. The six triads, M1 through M6, and
their characteristic chemical shifts (Table 2), constitute the
SRG region of GXM. The development of the chemotyping
system for C. neoformans was predicated on our ability to
identify and quantify the SRGs for GXM by using high-field
proton NMR.
Identification of SRGs by using proton NMR. The 1D pro-
ton spectrum of each GXM was recorded as illustrated for
C. neoformans isolate 150 in Fig. 4a (1D full spectrum with
SRG region marked). The SRG region of the proton spectrum
was selected; resolution enhancement and expansion of the
data were done to simplify the identification process (Fig. 4b).
The presence of SRGs M1 through M6 in the GXM proton
spectrum was determined by using the chemical-shift assign-
ments listed in Table 2. Two SRGs, M2 and M3 were identified
by using the data for the GXM of C. neoformans isolate 150
(Fig. 4b) and the data in Table 2. Similarly, 106 isolates were
investigated and the SRG distributions in individual GXMs
were determined (Table 3).
Quantitation of SRGs: PeakFit. The original proton NMR
data for the SRG region were analyzed by using PeakFit as
described in Materials and Methods. The PeakFit analysis
using the FELIX ASCII file generated from the primary pro-
ton NMR data for the SRG region recorded for the GXM
from C. neoformans isolate 150 is given in Fig. 5. The area for
each identifiable resonance appearing in the proton NMR
spectrum (Fig. 4) was assigned to a particular SRG based on its
characteristic proton chemical shifts, identified as described
above (Table 2). The area data depicted in Fig. 5 were used to
calculate the percent occurrence of the SRGs present in the
GXM from C. neoformans isolate 150 (Table 3). The analysis
was repeated for all the GXMs available, and the results were
tabulated (Table 3). The PeakFit data were normalized to
100%.
Order of preferences for entering SRG data in Table 3. The
PeakFit data were used to determine the order of preference
for entering the quantitative distribution of the SRGs in Table
3. The first order of preference was the identification of SRG
M1. The data were entered in descending order of area as-
signed to SRG M1. When SRGs M5 and M6 were also present,
they were listed without regard to their quantitative appear-
ance in the GXM. M5 and M6 were not used in determining
the order of preference here or in later entries, even in those
few cases where one of them was present as the primary com-
ponent, and this data set was defined as chemotype 1 (Chem1)
(Table 3). The data for the ensuing set of entries were selected
based on the concurrent appearance of M1 and M2, with the
relative area of M1 determining the order of preference (Table
3). This data set was defined as Chem2 (Table 3). The third
order of preference was based on the concurrent appearance
of M1, M2, and M3, with the relative area of M1 determining
the order of entry. This data set was defined as Chem3 (Table
3). The fourth order of preference was based on the sole
appearance of M2, and this data set was defined as Chem4
(Table 3). The fifth order of preference was based on the
appearance of M2 and M3, with the relative area of M2 de-
termining the order of entry, and this data set was defined as
Chem5 (Table 3). The sixth order of preference was based on
the appearance of M2, M3, and M4, with the relative area of
M2 determining the order of entry. Only two GXMs met these
criteria, and this data set was defined as Chem6 (Table 3). The
seventh order of preference was based on the appearance of
M3, and this data set was defined as Chem7 (Table 3). The
eighth, and final, order of preference was based on the appear-
FIG. 4. Full (a) and resolution-enhanced (b) 1D proton NMR spectrum of
C. neoformans isolate 150.
TABLE 2. Proton NMR chemical shifts of the SRG triads of
C. neoformans GXMs
SRG No.a
Chemical shift (ppm)
Mab Mb Mc
M1 32 5.241 6 0.002 5.193 6 0.003c 5.193 6 0.002c
M2 56 5.244 6 0.002 5.306 6 0.004 5.175 6 0.003
M3 45 5.208 6 0.003 5.325 6 0.005 5.138 6 0.004
M4 7 5.243 6 0.003 5.301 6 0.005 5.075 6 0.002
M5 26 5.217 6 0.002 5.192 6 0.003d 5.192 6 0.003d
M6 47 5.260 6 0.002 5.192 6 0.002e 5.117 6 0.002
a Number of GXMs analyzed to determine the chemical shifts of the SRG.
b Nomenclature is as presented in Fig. 1.
c In the M1 SRG, Ma and Mb are degenerate.
d In the M5 SRG, Mb and Mc are degenerate and overlap with Mb and Mc of
the M1 SRG.
e In the M6 SRG, Mb is degenerate with Mb and Mc of the M1 and M5 SRGs.
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TABLE 3. Assignment of SRGs M1 through M6 to chemotypes 1 through 8 by using PeakFit and the ANN
for the isolates described in Table 1a
Isolate M1 M2 M3 M4 M5 M6 SRG Total
Chem1
P0 100 M1
[72] [11] [16] [99]
24067 d1 100 M1
[75] [8] [22] [105]
24067 d2 100 M1
[73] [8] [20] [101]
24067 e 100 M1
[71] [6] [9] [17] [103]
24067 g 100 M1
[75] [9] [18] [104]
24067 f1 100 M1
[62] [8] [14] [10] [14] [108]
24067 f2 100 M1
[71] [23] [7] [101]
24067 c 100 M1
[76] [10] [18] [104]
24067 a 100 M1
[71] [5] [13] [16] [105]
24067 b 100 M1
[74] [8] [20] [102]
D529 79 21 M1
[72] [8] [22] [102]
1254 79 21 M1
[72] [20] [92]
9375 74 10 16 M1
[71] [10] [21] [102]
M0050 70 30 M1
[67] [18] [32] [117]
D52 65 35 M1
[66] [35] [101]
3168 68 8 24 M1
[72] [8] [21] [101]
127 64 14 22 M1
[72] [8] [22] [102]
J9a 59 41 M1
[59] [42] [101]
F12 57 11 32 M1
[66] [8] [24] [98]
NIH 37 56 11 33 M1
[35] [19] [4] [49] [107]
J9b 53 27 20 M1
[46] [30] [14] [90]
B3502 52 48 M1
[53] [45] [98]
Continued on following page
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TABLE 3—Continued
Isolate M1 M2 M3 M4 M5 M6 SRG Total
J9c 50 29 21 M1
[46] [26] [15] [87]
J22b 49 22 29 M1
[47] [8] [4] [48] [107]
J22a 39 18 43 M1
[33] [18] [3] [53] [107]
430 38 44 18 M1
[49] [36] [12] [97]
CDC92-159 38 28 34 M1
[39] [10] [8] [30] [77]
ATCC 28958 34 19 47 M1
[34] [16] [3] [54] [107]
ATCC 48184 32 16 52 M1
[20] [46] [3] [47] [116]
CDC92-232 31 69 M1
[30] [65] [95]
M0024 30 70 M1
[32] [64] [96]
98 27 20 53 M1
[32] [2] [54] [89]
ATCC 34875 27 25 48 M1
[25] [32] [3] [55] [115]
Chem2
J9d 63 18 19 M1.M2b
[66] [1] [22] [89]
SB4a 47 28 25 M1.M2
[24] [16] [40] [80]
M0025 46 29 25 M1.M2
[5] [40] [9] [16] [70]
SB6a 32 24 14 30 M1.M2
[29] [20] [7] [34] [90]
132 31 23 2 44 M1.M2
[19] [27] [2] [47] [95]
110 31 21 6 42 M1.M2
[23] [30] [3] [53] [112]
SB4c 28 28 12 36 M1.M2
[27] [23] [6] [34] [90]
M0095 19 59 22 M2.M1
[10] [54] [24] [88]
Chem3
M0051 32 29 18 21 M1.M2.M3
[16] [37] [3] [34] [90]
M0010 28 25 6 17 24 M1.M2.M3
[12] [63] [3] [4] [30] [112]
Continued on following page
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TABLE 3—Continued
Isolate M1 M2 M3 M4 M5 M6 SRG Total
M0062 25 17 8 20 30 M1.M2.M3
[18] [39] [2] [3] [38] [100]
SB6b 23 34 15 28 M2.M1.M3
[18] [33] [3] [42] [96]
M0046 23 18 4 30 25 M1.M2.M3
[12] [56] [3] [3] [29] [103]
M0027 23 46 31 M2.M3.M1
[2] [49] [17] [68]
M0013 19 38 15 6 22 M2.M1.M3
[2] [80] [15] [1] [7] [105]
AW 8 47 9 12 24 M2.M1.M3
[14] [37] [2] [5] [25] [83]
Chem4
MU-1 100 M2
[89] [14] [103]
201 100 M2
[5] [25] [85] [6] [10] [5] [136]
A24064 100 M2
[92] [92]
118 100 M2
[87] [87]
SB4b 77 23 M2
[72] [8] [80]
9759a 76 24 M2
[63] [16] [79]
9759 75 25 M2
[68] [12] [80]
M0029 74 26 M2
[76] [8] [84]
J11b 63 17 22 M2
[76] [12] [1] [8] [97]
A104 58 42 M2
[57] [35] [92]
Chem5
R1064 91 9 M2.M3
[83] [16] [99]
M0053 85 15 M2.M3
[84] [13] [97]
ATCC 62066 82 18 M2.M3
[86] [13] [99]
F113 81 19 M2.M3
[86] [17] [103]
B4538 76 11 13 M2.M3
[81] [15] [6] [102]
Continued on following page
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TABLE 3—Continued
Isolate M1 M2 M3 M4 M5 M6 SRG Total
TYCC 38-602 75 25 M2.M3
[76] [22] [98]
194 75 25 M2.M3
[75] [19] [94]
F27 75 25 M2.M3
[89] [14] [103]
F117 73 27 M2.M3
[86] [8] [94]
ATCC 6352 71 29 M2.M3
[84] [25] [109]
196 70 30 M2.M3
[76] [12] [88]
NU-2 69 31 M2.M3
[78] [20] [98]
A289 69 31 M2.M3
[69] [26] [95]
CDC92-64 67 33 M2.M3
[56] [35] [91]
ATCC 90126 65 35 M2.M3
[66] [35] [101]
6 65 14 21 M2.M3
[69] [21] [8] [98]
J11a 64 12 24 M2.M3
[78] [7] [10] [95]
M0048 63 37 M2.M3
[72] [31] [103]
371 60 40 M2.M3
[62] [37] [99]
CDC92-162 59 41 M2.M3
[55] [45] [100]
A288 58 20 11 11 M2.M3
[32] [8] [3] [8] [53]
NCPF 3168 52 48 M2.M3
[86] [14] [100]
CDC92-187 49 44 7 M2.M3
[56] [42] [2] [100]
150 45 55 M3.M2
[62] [41] [103]
A271 43 57 M3.M2
[39] [50] [7] [96]
ATCC 32608 39 46 15 M3.M2
[18] [70] [10] [2] [100]
Chem6
401 24 60 16 M3.M2.M4
[4] [55] [30] [89]
Continued on following page
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TABLE 3—Continued
Isolate M1 M2 M3 M4 M5 M6 SRG Total
C917 13 74 13 M3.M25M4
[21] [72] [13] [106]
Chem7
C24066 100 M3
[93] [6] [99]
Houpt 24066 100 M3
[93] [5] [98]
C24066W 100 M3
[16] [86] [5] [107]
Kuhl 94-8069 100 M3
[96] [96]
3939 100 M3
[93] [93]
3183 100 M3
[94] [94]
ATCC 24065 100 M3
[96] [96]
ATCC 24066 100 M3
[95] [95]
ATCC 32269 100 M3
[92] [92]
ATCC 34878 100 M3
[90] [90]
409 100 M3
[94] [94]
184 100 M3
[96] [96]
18 100 M3
[94] [94]
Chem8
D24067 79 21 M3.M4
[79] [17] [96]
298Warty 72 28 M3.M4
[87] [14] [101]
ATCC 34880 65 35 M3.M4
[69] [35] [104]
298 48 52 M3.M4
[49] [55] [104]
34 33 67 M3.M4
[32] [60] [92]
C24066T 100 M4
[60] [30] [90]
a Values are percentages. For each GXM file, values on the first line are the PeakFit results normalized to 100%; values on the second line are obtained directly from
the neural network analysis of the SRG region of the proton NMR spectrum and are enclosed in brackets.
b M1.M2, the area of M1 is greater than the area of M2. See Results, “Order of preference for entering SRG data in Table 3.”
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ance of M3 and M4, and this set of data was defined as Chem8
(Table 3). The one archetypal isolate containing M4 only was
included in this group.
Quantitation of SRGs: ANN model. Several specific ANN
models of the feed-forward multistaged backpropagation type
were considered (53). The architectures of these models differ
in the number of hidden neurons, the complexity of input
patterns, and the formulation of the output. The performances
of several models were investigated to determine the one most
suited for our study. Parameters such as hidden layer size, step
size, etc. (53) were optimized experimentally. Fifty different
networks were trained in order to determine the optimum
parameters. The optimum network consisted of 1,000 input
neurons, 5 hidden neurons, and 6 output neurons. A step size
of 0.01 was used without a momentum term (53). The 1,000
input neurons covered a small portion of the 1D proton spec-
trum between 5.0 and 5.5 ppm, representing the mannose
anomeric region (SRG). The results of the ANN analysis were
tabulated and appear in Table 3 in brackets.
Chemotype distribution. The distribution of the eight sug-
gested chemotypes (Chem1 through Chem8) in the 106 iso-
lates of C. neoformans investigated in this study is summarized
in Table 4.
DISCUSSION
Latex agglutination tests and enzyme immunoassays for the
detection of GXM in cerebral spinal fluid and serum, and
polyclonal and monoclonal antibodies for serotyping, have
been used for diagnostic and epidemiological studies (44). The
detection of antigen is diagnostic for infection by C. neofor-
mans. The continued presence of high antigen levels indicates
a poor prognosis for the patient, whereas antigen clearance is
indicative of a successful course of treatment (34). The com-
plete eradication of the organism by current treatment regi-
mens is unlikely, and relapse usually occurs. Comparative in-
vestigations of the immunochemistry, immunology, and
genetics of C. neoformans are intimately linked to GXM. In
turn, the results of these investigations are intrinsically related
to the chemical structure of GXM at the residue level. The
correlation between virulence, the course of the disease, the
severity of the disease, and the chemical structure of GXM has
not been studied. The recognition of the importance of GXM
structure served as the driving force for this study.
Currently, C. neoformans serotypes cannot be further subdi-
vided because the available serological reagents do not have
the discriminating power required to recognize structural vari-
ation in GXMs (38). This phenomenon is due to the fact that
although O-acetyl is only a minor contributor to the epitope
structure, it is a major determinant of the observed serological
activity; de-O-acetylated GXMs do not react with serotype-
specific factor sera (15, 16, 18). Therefore, the principal vari-
ations in structure, which are based on the disposition of the
sugar residues in GXM, are not detected. This lack of a strain-
typing method has prevented the demonstration of point
sources of infection that is required for epidemiological inves-
tigations of cryptococcosis (38). Bhattacharjee et al. (18) sug-
gested the occurrence of four discrete model structures, one
for each of the serologically defined types shown in Fig. 2 as
M1 through M4, and implied that heterogeneity may exist
between isolates. Heterogeneity, real or perceived, may be due
to the usual pitfalls encountered in the study of complex poly-
saccharides by classical methods of structural analysis used in
earlier studies (such as incomplete acid hydrolysis, differential
loss of certain residues over others, low yields by partial acid
hydrolysis, and incomplete methylation).
NMR spectroscopy, a nondestructive, highly discriminating
analytical method, was used by us to probe the fine structure of
de-O-acetylated polysaccharides. No secondary chemical reac-
tions, hydrolysis, or derivatization was required. In a series of
FIG. 5. PeakFit analysis of the SRG region of the 1D proton NMR spectrum of C. neoformans isolate 150.
TABLE 4. Suggested chemotypes of C. neoformans based
on the SRG concept
SRG class Other SRGs No. Chemotype
M1 M6 or M5 and M6 33 Chem1
M1/M2 M6 or M5 and M6 8 Chem2
M1/M2/M3 M6 or M5 and M6 or none 8 Chem3
M2 M6 10 Chem4
M2/M3 None or few M6 26 Chem5
M2/M3/M4 None 2 Chem6
M3 None 13 Chem7
M3/M4 or M4 None 6 Chem8
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in-depth studies, we demonstrated that heterogeneity in GXM
structure is the norm. NMR analysis identified sequences orig-
inally relegated to one serotype in other types. Structures
thought to occur in only one variety were commonly found in
the other variety. In addition, two other triads, M5 and M6,
were identified, and their structures were characterized by
NMR spectroscopy. The six triads, M1 through M6 (Fig. 2),
were used as a set of SRGs to develop the chemotyping system.
The proton NMR spectra obtained for de-O-acetylated GXMs
were resolution enhanced in order to determine precisely the
chemical shifts present in a GXM. The chemical-shift data
were used to identify which SRGs were present in a particular
GXM by comparison to the assignments found in Table 2.
Analysis of the SRG region of the original proton NMR spec-
trum was repeated by using PeakFit. The PeakFit analysis was
used to quantify the distribution of SRGs present in a partic-
ular GXM. A large selection of GXMs was used to create a
database for 106 GXMs (Table 3).
The SRG data formed a pattern of eight clusters based on
the preferences used to generate Table 3. Chem1 (33 isolates
[Table 4]) was determined by the presence of the SRG M1. M1
in Chem1 was almost always found associated with M6 or with
M6 and M5. M5 never occurred alone or without M1 in any
GXM. Chem2 (eight isolates [Table 4]) was determined by the
concurrent presence of SRGs M1 and M2. Chem2 isolates
were always associated with M6 or with M5 and M6. Chem3
(eight isolates [Table 4]) was determined by the concurrent
presence of SRGs M1, M2, and M3. Chem3 isolates were
associated with M6 in two cases and with M5 and M6 in one
case; in one instance, M5 and M6 were absent. Chem4 (10
isolates [Table 4]) was determined solely by the presence of
M2. In the Chem4 isolates, M6 was found associated with half
the isolates and M5 was never detected. Chem5 (26 isolates
[Table 4]) was determined by the presence of M2 and M3.
Only four isolates in Chem5 were found associated with M6;
M5 was never found. Chem6 (two isolates [Table 4]) was char-
acterized by the concurrent presence of M2, M3, and M4; M5
and M6 were absent. Chem7 (13 isolates [Table 4]) was deter-
mined by the presence of M3; M5 and M6 were absent. This
chemotype consisted of the largest structurally homogeneous
set of isolates. Chem8 (6 isolates [Table 4]) was determined by
the presence of M3 and M4; M5 and M6 were absent. One of
the isolates was an M4 archetype isolate but was included in
this chemotype. The data in Table 3 demonstrated that a con-
tinuum of SRGs characterized the GXMs of C. neoformans. A
blurred demarcation between the structural elements previ-
ously assigned specifically to one or the other of the two vari-
eties of C. neoformans (varieties neoformans and gattii) is ap-
parent. As the degree of substitution of the core structure with
Xyl increased, a concomitant decrease in the occurrence of
SRGs M5 and M6 was observed. The identification of GXM
archetype isolates was the exception rather than the rule. The
10 isolates in Chem7 that consisted of SRG M3 only were
exceptional. However, M3 was frequently associated with
Chem3, Chem5, Chem6, and Chem7.
Both the test set and the learning set of NMR data files,
which were analyzed previously by PeakFit, were used to eval-
uate the trained neural network. The quantitative distribution
of the SRGs obtained by the neural network (data in brackets)
was compared to the data obtained by PeakFit (Table 3). At
present there is not an absolute correspondence between the
data obtained by PeakFit and those obtained by the neural
network. In fact, a comparatively large percentage of M6 triad
was retrieved when we performed a validation test of the ANN
with a series of GXMs that essentially comprised only M1
triads (24067 isolates) (Tables 1 and 3). This phenomenon may
be due to the overlap of M6b resonance with the degenerate
M2b,c resonances (Table 2). Therefore, we know that training
needs to be modified in order to remove any remaining ambi-
guity in the output data obtained by the present ANN.
The results of the standard backpropagation model for the
ANN are not shown in Table 3 because of the large deviation
of the sum of the ratios for the SRGs from the target of 100%.
The sum of the ratios reported by the modified backpropaga-
tion model also diverged from the desired 100% value. But this
divergence was much less than that observed for the standard
backpropagation model. Although the ratios listed in Table 3
for the PeakFit analyses sum to 100%, this was accomplished
by the manual scaling of the initial results. We believe that the
small amount of residual chemical noise and resonance overlap
present in the spectra affects the results of all mathematical
analyses of the data.
An advantage of the ANN’s analysis of this type of data is
that it can be shown mathematically that the further the sums
of the ratios diverge from 100%, the less confidence one
should place in the results (30). Therefore, a confidence index
can be computed for each output. We did not scale the ANN
output data algebraically to give a sum of the ratios equal to
100% because we believe that the observed divergence carries
important information that could indicate the presence of con-
taminants and other possible artifacts.
In the future, we will refine the neural network by increasing
the size of the learning set and by using NMR data from
several archetypal isolates of C. neoformans that produce
GXMs with a single mannosyl triad in the SRG region of the
spectra. We will also conduct experiments using larger seg-
ments of the spectrum as input data for the ANN in an attempt
to increase the accuracy of the results. We plan to test the
accuracy of the trained ANN by using archetype GXMs to
prepare synthetic mixtures that contain predetermined ratios
of the various SRGs.
The correlation of chemotype, based on the distribution of
SRGs, with serotype was not possible because the O-acetyl
substituent is instrumental in determining the structure of the
epitope reactive with serological reagents. The GXM of
24066Tan is composed of M4 only and has no detectable acetyl
substitution. Therefore, we can conclude that M3 acetylation
fixed the conformation of M3 to produce the same epitope
structure created by O-4 substitution in M4.
The chemotyping system and the identification of subtypes
within each chemotype, based on the quantitative distribution
of the SRGs, could lead to (i) a better understanding of how
the polysaccharide antigens influence type 1 and type 2 T-cell
responses, (ii) a better understanding of how the polysaccha-
rides potentiate opportunistic infections in HIV-infected pa-
tients, (iii) the design of effective haptens for the preparation
of neoglycoconjugate vaccines, (iv) a better understanding of
how virulence is related to molecular structure, (v) the devel-
opment of a computer-assisted automated system for the che-
motyping of C. neoformans isolates and for the monitoring of
phenotype switching, (vi) the development of a new epidemi-
ological tool for the surveillance of cryptococcosis, and (vii) a
possible explanation of the variation in antigen titer deter-
mined by common diagnostic tests.
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